Peripheral arterial disease - Pipeline assessment and market forecasts to 2017

GlobalData, the industry analysis specialist, has released its new report, titled Peripheral Arterial Disease (PAD) - Pipeline Assessment and Market Forecasts to 2017, showing that the global PAD therapeutics market accounted for approximately $606 million in 2009. In 2001, the market was valued at $405 million and it increased at an approximate compound annual growth rate (CAGR) of 5.2% between 2001 and 2009.

The global PAD therapeutics market is expected to reach $1 billion by 2017, growing at a CAGR of 6.5% between 2009 and 2017. The primary factor contributing to the increase in growth over the forecast period is the increase in disease incidence and the launch of new first-in-class drugs.

Presently, the report notes, the therapeutic regimen for PAD consists of antiplatelet agents such as clopidogrel (Plavix, from Sanofi-Aventis) and ticlopidine (Ticlid, from Sanofi and Roche). Blood thinners such as pentoxifyline (Trental, also from Sanofi) and cilostazol (Pletal, from Otsuka) are also prescribed. Like most cardiovascular complications, aspirin is used as a complementary drug in combination with the above mentioned drugs.